CORE
Motivation-anchored education
Trial-specific content that connects asymptomatic disease to long-term outcomes. Visit-by-visit expectations. Burden translation so patients know what they signed up for and why it matters.
High volume masks silent attrition.
Diabetes. Cardiovascular. Respiratory. NASH.Large eligible populations make enrollment feel easy.The readiness challenge is hidden underneath.
The readiness profile.
Low perceived urgency. Long timelines stretching 26 to 52 weeks or more. Competing priorities from work, family, and daily life. Asymptomatic patients who feel no different whether they participate or not.
The central readiness gap: patients who are medically eligible but lack a compelling internal reason to persist through protocol demands that feel disproportionate to their lived experience of the disease. Motivation was never deeply established at enrollment, so it cannot sustain participation when burden accumulates.
Where dropout concentrates.
Mid-study, typically stages 5 and 6 of the trial lifecycle. The period where protocol burden compounds and the motivation that drove enrollment has long faded.
Patients do not drop out dramatically. They drift. Missed visits increase. Adherence to dosing schedules weakens. Communication response rates fall. By the time the signal is visible in traditional dashboards, the patient is already disengaged and recovery is unlikely.
What CORE and PRISM govern in common-disease trials.
CORE prepares patients to sustain a long protocol when the disease feels invisible. PRISM detects motivation decay early and flags the risk before drift becomes dropout, so the sponsor's team can intervene.
PRISM
Sustained motivation monitoring
Behavioral signal tracking across the full trial duration. Motivation decay detection through engagement, adherence, and communication patterns. Intervention before the patient disengages.
PRISM
Expectation recalibration
Adaptive touchpoints at protocol milestones where burden shifts or intensifies. Behavioral interventions calibrated to the moment, not generic reminders.
A 52-week NASH trial loses patients not because they cannot participate, but because nothing in their daily experience reminds them why they should. The disease is invisible. The protocol is not. The readiness model has to bridge that gap every week.
Frequently Asked Questions
Why do common disease trials have hidden readiness problems?
Common disease trials recruit from large eligible populations, which masks underlying readiness fragility. Patients with conditions like diabetes or cardiovascular disease often feel fine, making it difficult to sustain motivation across 26 or 52 week protocols. Dropout accumulates silently in mid-study because motivation was never deeply established.
Where does dropout typically concentrate?
Mid-study. The period where protocol burden compounds and the initial motivation that drove enrollment has faded. Patients do not drop out dramatically. They drift. By the time the signal is visible, the patient is already disengaged.
What role does CORE play in a common disease trial?
CORE produces trial-specific education that anchors motivation to long-term outcomes, translates protocol burden into daily-life terms, and prepares patients for the visit-by-visit reality of a long protocol. Multilingual and amendment-resilient.
What role does PRISM play in a common disease trial?
PRISM monitors motivation decay across the full trial duration through behavioral signals, detects adherence weakening before traditional dashboards surface it, and triggers expectation recalibration at protocol milestones.
Send us your protocol and site list.
In two days, you get three execution diagnostics on your program.
01 · The Baseline
Trial Readiness Index
How likely each eligible patient cluster is to activate, persist, and complete, before any intervention.
02 · The Diagnosis
Readiness Friction Map
The barriers most likely to suppress activation, enrollment, and completion in each cluster, and how to mitigate them.
03 · The Prescription
Readiness
Blueprint
Which clusters to target, which barriers to address, which interventions to deploy, and what completion lift to expect.